The Evidence for Disease Modification in Parkinson's Disease

被引:8
作者
Lew, Mark F. [1 ]
机构
[1] Keck USC Sch Med, Dept Neurol, Los Angeles, CA 90033 USA
关键词
clinical trials; Parkinson's disease (PD); neuroprotection; DELAYED-START; PROGRESSION; DOPAMINE; EXERCISE; NEUROPLASTICITY; NEUROPROTECTION; PRAMIPEXOLE; SELEGILINE; RASAGILINE; NEURONS;
D O I
10.3109/00207454.2011.620194
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Disease modification or slowing the progression of any neurodegenerative disorder represents a dire unmet need. There have been trials for several decades specifically designed to help evaluate whether a specific therapy might be able to slow the progression of Parkinson's disease (PD) or be disease modifying. Trials evaluating the use of coenzyme Q10, pramipexole, and levodopa suggest that these medications offer symptomatic benefit uniquely, while other studies reveal that rasagiline and selegiline may be disease modifying. This review will discuss in detail the design and results of clinical trials for varied medical therapies that were specifically undertaken to discern whether a particular treatment might be disease modifying in the treatment of PD.
引用
收藏
页码:18 / 26
页数:9
相关论文
共 50 条
  • [41] Treatment of early Parkinson's disease
    Pahwa, Rajesh
    Lyons, Kelly E.
    CURRENT OPINION IN NEUROLOGY, 2014, 27 (04) : 442 - 449
  • [42] A systematic review of biomarkers for disease progression in Parkinson's disease
    McGhee, David J. M.
    Royle, Pamela L.
    Thompson, Paul A.
    Wright, David E.
    Zajicek, John P.
    Counsell, Carl E.
    BMC NEUROLOGY, 2013, 13
  • [43] Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study
    Schapira, Anthony H. V.
    Albrecht, Stefan
    Barone, Paolo
    Comella, Cynthia L.
    McDermott, Michael P.
    Mizuno, Yoshikuni
    Poewe, Werner
    Rascol, Olivier
    Marek, Kenneth
    MOVEMENT DISORDERS, 2010, 25 (11) : 1627 - 1632
  • [44] Biomarkers in Parkinson's disease: an update
    Shtilbans, Alexander
    Henchcliffe, Claire
    CURRENT OPINION IN NEUROLOGY, 2012, 25 (04) : 460 - 465
  • [45] Initial treatment of Parkinson's disease
    Tarsy D.
    Current Treatment Options in Neurology, 2006, 8 (3) : 224 - 235
  • [46] New Physiotherapy Interventions in Parkinson's Disease - What is the Evidence?
    Kuether, G.
    PHYSIKALISCHE MEDIZIN REHABILITATIONSMEDIZIN KURORTMEDIZIN, 2015, 25 (01) : 11 - 18
  • [47] Parkinson's Disease: Risk Factor Modification and Prevention
    Rajan, Suraj
    Kaas, Bonnie
    SEMINARS IN NEUROLOGY, 2022, 42 (05) : 626 - 638
  • [48] Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease
    Evans, Jonathan R.
    Barker, Roger A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (08) : 1249 - 1258
  • [49] Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
    Mischley, Laurie K.
    Lau, Richard C.
    Shankland, Eric G.
    Wilbur, Timothy K.
    Padowski, Jeannie M.
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 (02) : 289 - 299
  • [50] New Agents Promote Neuroprotection in Parkinson's Disease Models
    Miranda Santos, Claudia Maria
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2012, 11 (04) : 410 - 418